Wide Ranks

CABA

Cabaletta Bio, Inc.

3.01

Top Statistics
Market Cap 147 M Forward PE -1.12 Revenue Growth 0.00 %
Current Ratio 11.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1130 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 203 M Total Cash Per Share 4.16 Total Debt 7 M
Total Debt To Equity 3.71 Current Ratio 11.52 Book Value Per Share 4.94
All Measures
Short Ratio 426.00 % Message Board Id finmb_590735322 Shares Short Prior Month 5 M
Return On Equity -0.4816 City Philadelphia Uuid 6fe46e50-561f-3aea-a102-2503a6e5bebe
Previous Close 2.42 First Trade Date Epoch Utc 1 B Book Value 4.94
Beta 2.42 Total Debt 7 M Volume 4 M
Price To Book 0.6094 Fifty Two Week Low 1.76 Total Cash Per Share 4.16
Shares Short Previous Month Date 1 B Target Median Price 24.00 Audit Risk 6
Max Age 86400 Recommendation Mean 1.17 Sand P52 Week Change 0.3133
Target Mean Price 22.10 Net Income To Common -89983000 Short Percent Of Float 0.0784
Implied Shares Outstanding 48 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 3 M Average Volume10days 3 M Total Cash 203 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0310 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 2.42 Target Low Price 10.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.93 Open 2.60 Free Cashflow -45623500
State PA Dividend Yield 0.00 % Return On Assets -0.3113
Time Zone Short Name EST Board Risk 10 Trailing Eps -2.16
Day Low 2.48 Address1 2929 Arch Street Shares Outstanding 48 M
Compensation Risk 9 Price Hint 4 Target High Price 35.00
Website https://www.cabalettabio.com 52 Week Change -0.8125 Average Volume 1 M
Forward Eps -2.40 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1135.40 % Is_sp_500 False Regular Market Day High 3.05
Profit Margins 0.00 % Debt To Equity 3.71 Fifty Two Week High 26.35
Day High 3.05 Shares Short 3 M Regular Market Open 2.60
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0759 Operating Cashflow -73829000 Currency USD
Time Zone Full Name America/New_York Market Cap 147 M Is_nasdaq_100 False
Zip 19104 Quote Type EQUITY Industry Biotechnology
Long Name Cabaletta Bio, Inc. Overall Risk 9 Regular Market Day Low 2.48
Held Percent Institutions 1.00 Current Price 3.01 Address2 Suite 600
Enterprise To Ebitda 0.1130 Financial Currency USD Current Ratio 11.52
Industry Disp Biotechnology Number Of Analyst Opinions 10 Country United States
Float Shares 41 M Two Hundred Day Average 9.75 Governance Epoch Date 1 B
Enterprise Value -11177016 Forward PE -1.12 Regular Market Volume 4 M
Ebitda -98614000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.

It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.

It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co.

, Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.

Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.